CTOs on the Move

Qosina Corporation

www.qosmedix.com

 
Qosina Corporation is a Edgewood, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.qosmedix.com
  • 150 Executive Dr Ste Q
    Edgewood, NY USA 11717
  • Phone: 631.242.3270

Executives

Name Title Contact Details

Similar Companies

Simavita

Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative world first solution for the management of urinary incontinence, with a focus on the elderly. Our flagship product is the SIM™ platform technology, an instrumented Incontinence assessment application that provides evidence based Incontinence management care plans to the residential aged care market.   Simavita is committed to continuously innovating and expanding its core SIM™ platform technology to improve the level of Incontinence care, create efficiencies, promote effective utilisation of our society`s finite resources and enhance the dignity of care for our ageing population.

180 Medical Inc

180 Medical Inc is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pace Tech

Pace Tech is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarion Medical Technologies Inc

Clarion Medical Technologies Inc is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scanadu

Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to develop a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. Unveiled in November 2012, the company is working to ensure this is the last generation to know so little about our health. The product portfolio includes the Scanadu Scout vital sign monitor and Scanadu Urine, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study, followed by clinical studies for the company’s road to FDA approval.